Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

New chronic lymphocytic leukaemia therapies: Does measurable residual disease testing accurately predict progression-free survival

Yun Wang, Chunhua Li, Robert Gale, Qi Liang, Neil Kay, Victoria Wang, Qianqian Huang, Yiling Song, Weida Wang, Yang Liang

Blood (2025) 146 (Supplement 1): 2132.

https://doi.org/10.1182/blood-2025-2132

Published: 2025

Journal Articles

Profiling drug sensitivity in CLL B cells after BTK inhibitor progression using a novel drug panel

Weiguo Han, Emmanuel Contreras Guzman, Aisharya Bhattacharya, Sutapa Sinha, Zhiquan Wang, Kari Rabe, Stephen Anthony, Nathanael Gray, Gerald Crabtree, Esteban Braggio, Saad Kenderian, Sameer Parikh, Neil Kay

Blood (2025) 146 (Supplement 1): 7407.

https://doi.org/10.1182/blood-2025-7407

Published: 2025

Journal Articles

Genomic profiling in CLL patients after BTK inhibitor progression identifies enrichment of mutations in MAPK pathway and epigenetic regulators

Daniel Bihnam, Daniela Trujillo Loaiza, Laura Bruins, Sochilt Brown, Zhiquan Wang, Saad Kenderian, Neil Kay, Sameer Parikh, Esteban Braggio

Blood (2025) 146 (Supplement 1): 5660.

https://doi.org/10.1182/blood-2025-5660

Published: 2025

Journal Articles

Systematic molecular profiling to identify determinants of response to ibrutinib

Blood (2025) 146 (Supplement 1): 3881.

https://doi.org/10.1182/blood-2025-3881

Published: 2025

Journal Articles

Venetoclax-obinutuzumab in frontline and R/R CLL: Outcomes compared to age- and sex-matched general population

Blood (2025) 146 (Supplement 1): 3905.

https://doi.org/10.1182/blood-2025-3905

Published: 2025

Journal Articles

Real-world (RW) use of fixed-duration (FD) ibrutinib+venetoclax (Ibr+Ven) in patients (pts) with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Pooled analysis of REALITY-worldwide (WW) and REALITY-2 prospective cohort studies

Blood (2025) 146 (Supplement 1): 3903.

https://doi.org/10.1182/blood-2025-3903

Published: 2025

Journal Articles

Ibrutinib enhances 41BB-costimulated CART19 function and persistence through immune reprogramming: Insights from the phase 3 ECOG-ACRIN E1912 clinical Trial

Blood (2025) 146 (Supplement 1): 2101.

https://doi.org/10.1182/blood-2025-2101

Published: 2025

Journal Articles

Genetic analysis of B and T cell subsets from CLL patients prior to and at Richter's transformation

Sutapa Sinha, Panwen Wang, Hugues Sicotte, Brianna Finke, Heather Darby, Elijah Blonigen, Miles Del Busso, Zhiquan Wang, Min Shi, Sameer Parikh, Wei Ding, Saad Kenderian, Neil Kay

Blood (2025) 146 (Supplement 1): 2099.

https://doi.org/10.1182/blood-2025-2099

Published: 2025

Journal Articles

Non-CLL-type MBL and chip are associated precursor conditions: Insights from Mayo Clinic's MBL screening cohort

Blood (2025) 146 (Supplement 1): 128.

https://doi.org/10.1182/blood-2025-128

Published: 2025

Journal Articles

Pirtobrutinib versus usual care for patients with richter transformation of chronic lymphocytic leukemia: Inverse probability of treatment weighting-based analysis of BRUIN trial and mayo observational cohort

Yucai Wang, Kari Rabe, Paul Hampel, Lindsey Roeker, Jihao Zhou, Suheil Albert Atallah-Yunes, Susan Schwager, Min Shi, Curtis Hanson, Rebecca King, Cinthya Mendoza Zepeda, Saad Kenderian, Eli Muchtar, Neil Kay, Amber Koehler, Amy Behnken, Catherine Coddington, Susan Slager, Sameer Parikh

Blood (2025) 146 (Supplement 1): 5673.

https://doi.org/10.1182/blood-2025-5673

Published: 2025

Journal Articles

Progression of disease within 36 months (POD36) of starting first-line targeted therapy independently predicts poor overall survival in patients with chronic lymphocytic leukemia (CLL)

Blood (2025) 146 (Supplement 1): 5667.

https://doi.org/10.1182/blood-2025-5667

Published: 2025

Journal Articles

Tumor-derived microRNA-125a impairs CART cell function and predicts treatment failure in B cell malignancies

Blood (2025) 146 (Supplement 1): 2321.

https://doi.org/10.1182/blood-2025-2321

Published: 2025

Journal Articles

IL-4 epigenetically reprograms CART19-28ζ cells to drive dysfunction

Blood (2025) 146 (Supplement 1): 2338.

https://doi.org/10.1182/blood-2025-2338

Published: 2025

Journal Articles

FISH Scoring for CLL: Comparison of Methods That Assess Round Versus Non-Round Nuclei,

Patricia T. Greipp, D.O., Stephanie A. Smoley, Neil Kay, MD, Clive S. Zent, MD, Jeannette E. Eckel-Passow, Ph.D., Ruchi G. Sharma, Daniel L. Van Dyke, Ph.D.

Blood (2011) 118 (21): 3538.

https://doi.org/10.1182/blood.V118.21.3538.3538

Published: 2011

Journal Articles

Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia

Chris L. Pashos, PhD, Christopher R Flowers, MD, Mark Weiss, MD, Nicole Lamanna, MD, Charles M Farber, MD, PhD, Thomas J. Kipps, M.D., Ph.D, Susan Lerner, MS, BA, Neil Kay, MD, Jeff Porte Sharman, MD, David L. Grinblatt, MD, Ian W. Flinn, MD, PhD, Mark Kozloff, MD, Arlene S Swern, PhD, Zeba M. Kahn, Ph.D, Thomas K. Street, RPh, Kristen A Sullivan, MBA, Gale Harding, MA, Michael J Keating, MD

Blood (2011) 118 (21): 2085.

https://doi.org/10.1182/blood.V118.21.2085.2085

Published: 2011

Journal Articles

Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL,

Tait D. Shanafelt, MD, Mark C Lanasa, MD, PhD, Clive S. Zent, MD, Jose F. Leis, MD, PhD, Timothy G Call, MD, Betsy R. LaPlant, Han Tun, MD, Deborah A. Bowen, Diane F. Jelinek, Ph.D., Curtis A. Hanson, MD, Neil Kay, MD

Blood (2011) 118 (21): 3898.

https://doi.org/10.1182/blood.V118.21.3898.3898

Published: 2011

Journal Articles

Lenalidomide Consolidation Appears to Prolong Time to Retreatment After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL,

Tait D. Shanafelt, MD, Han Tun, MD, Curtis A. Hanson, MD, Clive S. Zent, MD, Jose F. Leis, MD, PhD, Timothy G Call, MD, Betsy R. LaPlant, Deborah Bowen, EmilyS S Pavey, Diane F. Jelinek, Ph.D., Neil Kay, MD

Blood (2011) 118 (21): 3899.

https://doi.org/10.1182/blood.V118.21.3899.3899

Published: 2011

Journal Articles

Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Prospective Case-Control Study of Newly Diagnosed Patients,

Jonathan Moreira, MD, Kari Rabe, MS, James R Cerhan, MD, PhD, Curtis A. Hanson, MD, Timothy G Call, MD, Clive S. Zent, MD, Jose F. Leis, MD, PhD, Deborah A. Bowen, John Wilson, MD, Neil Kay, MD, Susan Schwager, Randy F Wendt, Susan L Slager, PhD, Tait D. Shanafelt, MD

Blood (2011) 118 (21): 3903.

https://doi.org/10.1182/blood.V118.21.3903.3903

Published: 2011

Journal Articles

Mesenchymal Stromal Cells Derived From Chronic Lymphocytic Leukemic Patients Express Different Genes and Produce Different Cytokines Compared to MSC Derived From Normal Subjects,

Wei Ding, MD, PhD, Traci Sassoon, Esteban Braggio, PhD, Charla Secreto, Neil Kay, MD

Blood (2011) 118 (21): 3872.

https://doi.org/10.1182/blood.V118.21.3872.3872

Published: 2011

Journal Articles

Prevalence of MBL Increases Over Time In Relatives of CLL Families,

Susan L Slager, PhD, Mark C Lanasa, MD, PhD, Sallie D. Allgood, MS, Sara J Achenbach, Aaron Norman, MS, Celine M Vachon, PhD, Lynn Goldin, PhD, Jose F. Leis, MD, PhD, Neil Kay, MD, J. Brice Weinberg, MD, Kari Rabe, MS, Timothy G. Call, MD, James R Cerhan, MD, PhD, Tait D. Shanafelt, MD, Neil E Caporaso, MD, Gerald E Marti, MD, PhD, Curtis A. Hanson, MD

Blood (2011) 118 (21): 3881.

https://doi.org/10.1182/blood.V118.21.3881.3881

Published: 2011

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

New chronic lymphocytic leukaemia therapies: Does measurable residual disease testing accurately predict progression-free survival

Profiling drug sensitivity in CLL B cells after BTK inhibitor progression using a novel drug panel

Genomic profiling in CLL patients after BTK inhibitor progression identifies enrichment of mutations in MAPK pathway and epigenetic regulators

Systematic molecular profiling to identify determinants of response to ibrutinib

Venetoclax-obinutuzumab in frontline and R/R CLL: Outcomes compared to age- and sex-matched general population

Real-world (RW) use of fixed-duration (FD) ibrutinib+venetoclax (Ibr+Ven) in patients (pts) with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Pooled analysis of REALITY-worldwide (WW) and REALITY-2 prospective cohort studies

Ibrutinib enhances 41BB-costimulated CART19 function and persistence through immune reprogramming: Insights from the phase 3 ECOG-ACRIN E1912 clinical Trial

Genetic analysis of B and T cell subsets from CLL patients prior to and at Richter's transformation

Non-CLL-type MBL and chip are associated precursor conditions: Insights from Mayo Clinic's MBL screening cohort

Pirtobrutinib versus usual care for patients with richter transformation of chronic lymphocytic leukemia: Inverse probability of treatment weighting-based analysis of BRUIN trial and mayo observational cohort

Progression of disease within 36 months (POD36) of starting first-line targeted therapy independently predicts poor overall survival in patients with chronic lymphocytic leukemia (CLL)

Tumor-derived microRNA-125a impairs CART cell function and predicts treatment failure in B cell malignancies

IL-4 epigenetically reprograms CART19-28ζ cells to drive dysfunction

FISH Scoring for CLL: Comparison of Methods That Assess Round Versus Non-Round Nuclei,

Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia

Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL,

Lenalidomide Consolidation Appears to Prolong Time to Retreatment After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL,

Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Prospective Case-Control Study of Newly Diagnosed Patients,

Mesenchymal Stromal Cells Derived From Chronic Lymphocytic Leukemic Patients Express Different Genes and Produce Different Cytokines Compared to MSC Derived From Normal Subjects,

Prevalence of MBL Increases Over Time In Relatives of CLL Families,

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only